Pfizer drops its B7-H4 conjugate
Felmetatug vedotin’s exit could be bad news for Mersana.
The month ahead: February’s upcoming events
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
AstraZeneca doubles down on GPC3
The company takes its T-cell engager into the clinic, just as Roche and Sanofi exit.
FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
NextCure joins the B7-H4 brigade
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
